L&K Biomed KRX:156100KOSDAQ

엘앤케이바이오 · Korean news coverage and regulatory filings, organized.

Articles, 24h1
Articles, 7 days8
DART filings, 7 days0
Articles tracked47since Sep 11

In Q2 2026, L&K Biomed reported revenue of ₩11.7bn, up 3.7% year on year, and operating profit of ₩1.3bn. L&K Biomed (엘앤케이바이오) appeared in 8 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 12 articles. The most common catalyst was contracts & orders (5). It was most often mentioned alongside 글로벌테크놀로지.

Filing signals Major holder adding Screener

L&K Biomed quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩11.7bn+3.7%₩1.3bn
margin 10.9%
₩8.0bn
Q1 2026₩9.5bn+6.8%₩106m
margin 1.1%
₩7.9bn
Q4 2025 derived₩8.6bn-14.1%−₩1.2bn
margin −13.9%
−₩16.4bn
Q3 2025₩10.1bn+3.6%₩338m
margin 3.4%
₩2.6bn
Q2 2025₩11.3bn+57.4%₩1.7bn
margin 15.2%
−₩2.3bn
Q1 2025₩8.9bn-2.6%−₩145m
margin −1.6%
−₩734m
Q4 2024 derived₩10.0bn+40.9%₩569m
margin 5.7%
₩5.8bn
Q3 2024₩9.7bn+38.1%₩1.3bn
margin 12.9%
−₩827m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

L&K Biomed top stories 2 weeks, by number of outlets

  1. 1
    엘앤케이바이오, 메드트로닉과 판매 에이전시 계약
    6 outlets · 6 articlesFirst report Oct 29 09:27 뉴시스경제
  2. 2
  3. 3
    엘앤케이바이오, NASS서 경추 임플란트 美 사업 확대 논의
    1 outlets · 1 articlesFirst report Oct 19 10:34 메디파나뉴스
  4. 4
    엘앤케이바이오, NASS서 북미 사업 구체화…차세대 경추 제품군 확장
    1 outlets · 1 articlesFirst report Oct 19 10:34 한스경제
  5. 5
    엘앤케이바이오, 美 'NASS' 참가…'블루엑스-C' 등 출품
    1 outlets · 1 articlesFirst report Oct 19 15:27 뉴시스경제
  6. 6
    엘앤케이바이오, 북미척추학회 참가…'블루엑스-C' 등 소개
    1 outlets · 1 articlesFirst report Oct 19 16:08 데일리한국

Latest L&K Biomed news Korean headlines